| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2e893abcc9018a3fe6594eebd496cba |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-397
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-397
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2020-01-29^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-01-19^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47bb5df93608774a5afd2f7ce07e9d67 |
| publicationDate |
2021-01-19^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10894028-B2 |
| titleOfInvention |
Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
| abstract |
In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof. |
| priorityDate |
2012-06-29^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |